spironolactone has been researched along with Breast Neoplasms in 23 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To provide dermatologists and oncologists with a foundation for practical understanding and uses of 5α-reductase inhibitors and spironolactone for breast cancer patients and survivors receiving endocrine therapies (ETs), including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy." | 9.01 | Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. ( Freites-Martinez, A; Geer, EB; Goldfarb, S; Lacouture, ME; Rozner, RN; Shapiro, J, 2019) |
| "Spironolactone is used off-label for androgenic alopecia because of its ability to arrest hair loss progression and long-term safety profile." | 7.96 | Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. ( Bovonratwet, P; Friedman, AJ; Gu, A; Moawad, G; Silverberg, JI; Wei, C, 2020) |
| "This study did not find evidence for breast cancer associated with spironolactone." | 7.91 | Breast cancer and spironolactone: an observational postmarketing study. ( Amar, J; Bouhanick, B; Chebane, L; Montastruc, F; Montastruc, JL; Rousseau, V; Sabatier, P, 2019) |
| "To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment." | 7.78 | Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| "To investigate whether exposure to spironolactone treatment affects the risk of incident breast cancer in women over 55 years of age." | 7.78 | Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. ( Macdonald, TM; Mackenzie, IS; Morant, S; Thompson, A; Wei, L, 2012) |
| "Thirteen of 15 patients with malignant ascites achieved an excellent response to spironolactone, with an increase in urinary sodium excretion rates from less than 35 mEq/d before treatment to between 50 and 245 mEq/d after treatment." | 7.66 | Control of malignant ascites with spironolactone. ( Greenway, B; Johnson, PJ; Williams, R, 1982) |
| "Among the four human breast cancer cell lines tested (MCF-7, T-47D, ZR-75-1, and MDA-MB-435s), the ZR-75-1 cells were selectively insensitive to the antiproliferative actions of 2-MeO-E2, although these cells had a similar sensitivity as other cell lines to several other anticancer agents (5-fluorouracil, mitomycin C, doxorubicin, colchicine, vinorelbine, and paclitaxel)." | 5.33 | Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause. ( Lee, WJ; Liu, ZJ; Zhu, BT, 2005) |
| "Frusemide 20mg/Spironolactone 50 mg), every other day for 4 weeks." | 5.27 | The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer ( Alhanafy, AM; Khalil, A; Labeeb, A, 2018) |
| "While originally approved for the management of heart failure, hypertension, and edema, spironolactone is commonly used off label in the management of acne, hidradenitis, androgenetic alopecia, and hirsutism." | 5.22 | Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. ( Barbieri, JS; Bommareddy, K; Hamade, H; Lopez-Olivo, MA; Tosh, T; Wehner, M, 2022) |
| "To provide dermatologists and oncologists with a foundation for practical understanding and uses of 5α-reductase inhibitors and spironolactone for breast cancer patients and survivors receiving endocrine therapies (ETs), including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy." | 5.01 | Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. ( Freites-Martinez, A; Geer, EB; Goldfarb, S; Lacouture, ME; Rozner, RN; Shapiro, J, 2019) |
| "Spironolactone is used off-label for androgenic alopecia because of its ability to arrest hair loss progression and long-term safety profile." | 3.96 | Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. ( Bovonratwet, P; Friedman, AJ; Gu, A; Moawad, G; Silverberg, JI; Wei, C, 2020) |
| "This study did not find evidence for breast cancer associated with spironolactone." | 3.91 | Breast cancer and spironolactone: an observational postmarketing study. ( Amar, J; Bouhanick, B; Chebane, L; Montastruc, F; Montastruc, JL; Rousseau, V; Sabatier, P, 2019) |
| "To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment." | 3.78 | Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| "To investigate whether exposure to spironolactone treatment affects the risk of incident breast cancer in women over 55 years of age." | 3.78 | Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. ( Macdonald, TM; Mackenzie, IS; Morant, S; Thompson, A; Wei, L, 2012) |
| "Thirteen of 15 patients with malignant ascites achieved an excellent response to spironolactone, with an increase in urinary sodium excretion rates from less than 35 mEq/d before treatment to between 50 and 245 mEq/d after treatment." | 3.66 | Control of malignant ascites with spironolactone. ( Greenway, B; Johnson, PJ; Williams, R, 1982) |
| "Among the four human breast cancer cell lines tested (MCF-7, T-47D, ZR-75-1, and MDA-MB-435s), the ZR-75-1 cells were selectively insensitive to the antiproliferative actions of 2-MeO-E2, although these cells had a similar sensitivity as other cell lines to several other anticancer agents (5-fluorouracil, mitomycin C, doxorubicin, colchicine, vinorelbine, and paclitaxel)." | 1.33 | Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause. ( Lee, WJ; Liu, ZJ; Zhu, BT, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (34.78) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Bommareddy, K | 1 |
| Hamade, H | 1 |
| Lopez-Olivo, MA | 1 |
| Wehner, M | 1 |
| Tosh, T | 1 |
| Barbieri, JS | 1 |
| Sabatier, P | 1 |
| Amar, J | 2 |
| Montastruc, F | 1 |
| Rousseau, V | 1 |
| Chebane, L | 1 |
| Bouhanick, B | 1 |
| Montastruc, JL | 1 |
| Angoulvant, T | 1 |
| Boivin, JM | 1 |
| Amar, L | 1 |
| Lantelme, P | 1 |
| Blacher, J | 1 |
| Plu-Bureau, G | 1 |
| Vehier, CM | 1 |
| Wei, C | 1 |
| Bovonratwet, P | 1 |
| Gu, A | 1 |
| Moawad, G | 1 |
| Silverberg, JI | 1 |
| Friedman, AJ | 1 |
| Heymann, WR | 1 |
| Rozner, RN | 1 |
| Freites-Martinez, A | 1 |
| Shapiro, J | 1 |
| Geer, EB | 1 |
| Goldfarb, S | 1 |
| Lacouture, ME | 1 |
| Alhanafy, AM | 1 |
| Labeeb, A | 1 |
| Khalil, A | 1 |
| Biggar, RJ | 2 |
| Andersen, EW | 1 |
| Wohlfahrt, J | 1 |
| Melbye, M | 1 |
| Akpek, M | 1 |
| Ozdogru, I | 1 |
| Sahin, O | 1 |
| Inanc, M | 1 |
| Dogan, A | 1 |
| Yazici, C | 1 |
| Berk, V | 1 |
| Karaca, H | 1 |
| Kalay, N | 1 |
| Oguzhan, A | 1 |
| Ergin, A | 1 |
| Kluger, N | 1 |
| Jacot, W | 1 |
| Frouin, E | 1 |
| Rigau, V | 1 |
| Poujol, S | 1 |
| Dereure, O | 1 |
| Guillot, B | 1 |
| Romieu, G | 1 |
| Bessis, D | 1 |
| Mackenzie, IS | 1 |
| Macdonald, TM | 1 |
| Thompson, A | 1 |
| Morant, S | 1 |
| Wei, L | 1 |
| Fanta, S | 1 |
| ABBES, M | 1 |
| CAMBON, P | 1 |
| PAILLAUD, F | 1 |
| Liu, ZJ | 1 |
| Lee, WJ | 1 |
| Zhu, BT | 1 |
| Merino Angulo, J | 1 |
| Bilbao Ercoreca, F | 1 |
| del Villar Negro, A | 1 |
| de la Riva Aguinaco, C | 1 |
| Aguirre Errasti, C | 1 |
| Molinatti, GM | 1 |
| Biffignandi, P | 1 |
| Massucchetti, C | 1 |
| Greenway, B | 1 |
| Johnson, PJ | 1 |
| Williams, R | 1 |
| Quietzsch, D | 1 |
| Capron, MH | 1 |
| Lauga, J | 1 |
| Loube, SD | 1 |
| Quirk, RA | 1 |
| Jick, H | 1 |
| Armstrong, B | 1 |
| Namer, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259] | Phase 4 | 264 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Protective Effects of Spironolactone Against Anthracycline Induced Cardiomyopathy[NCT02053974] | Phase 4 | 90 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Randomized Controlled Trial to Evaluate Effectiveness of Cooling Cap to Prevent Permanent Chemotherapy-induced Alopecia Among Breast Cancer Patients[NCT04678544] | 170 participants (Actual) | Interventional | 2020-12-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for spironolactone and Breast Neoplasms
| Article | Year |
|---|---|
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
Topics: Acne Vulgaris; Aged; Breast Neoplasms; Female; Hirsutism; Humans; Male; Middle Aged; Prostatic Neopl | 2022 |
Topics: Age Factors; Antihypertensive Agents; Blood Pressure; Breast Neoplasms; Female; Humans; Hypertension | 2019 |
Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Antineoplastic Agents; Breast Neoplasms; Female; Finasteride | 2019 |
Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Digoxin; Estrogens; Female; | 2012 |
[Intracellular and extracellular proteins binding androgenic hormones. Biochemical properties and clinical significance].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Androgen-Binding Protein; Androgen-Insensitivity Syndrom | 1983 |
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; | 1988 |
2 trials available for spironolactone and Breast Neoplasms
| Article | Year |
|---|---|
The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer
Topics: Aged; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Diuretics; Egypt; Female; Furosemide; Huma | 2018 |
Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathies; Double-Blind | 2015 |
Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathies; Double-Blind | 2015 |
Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathies; Double-Blind | 2015 |
Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathies; Double-Blind | 2015 |
15 other studies available for spironolactone and Breast Neoplasms
| Article | Year |
|---|---|
Breast cancer and spironolactone: an observational postmarketing study.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Breast Neoplasms; Diuretics; Femal | 2019 |
Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Breast Neoplasms; Databases, Factual; Female; Humans; Midd | 2020 |
Spironolactone and breast cancer: Fear not!
Topics: Breast Neoplasms; Fear; Female; Hirsutism; Humans; Neoplasm Recurrence, Local; Retrospective Studies | 2020 |
Spironolactone use and the risk of breast and gynecologic cancers.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Denmark; Drug Prescriptions; Femal | 2013 |
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.
Topics: Animals; Breast Neoplasms; Diuretics; Family Practice; Female; Heart Failure; Humans; Hypertension; | 2012 |
[Increased breast cancer risk caused by spironolactone?].
Topics: Breast Neoplasms; Cohort Studies; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Hyper | 2012 |
[APPLICATION OF ANTI-ALDOSTERONE DIURETICS TO THE TREATMENT OF LOCALIZED EDEMA OF THE EXTREMITIES IN CANCER PATIENTS].
Topics: Aldosterone; Breast Neoplasms; Diuretics; Edema; Extremities; Female; Humans; Mastectomy; Mineraloco | 1965 |
Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
Topics: 17-Hydroxysteroid Dehydrogenases; 2-Methoxyestradiol; Breast Neoplasms; Cell Line, Tumor; Cell Proli | 2005 |
[Bilateral metastatic gynecomastia. An unusual manifestation of small-cell pulmonary carcinoma].
Topics: Breast Neoplasms; Carcinoma, Small Cell; Gynecomastia; Humans; Liver Cirrhosis, Alcoholic; Lung Neop | 1983 |
Control of malignant ascites with spironolactone.
Topics: Abdominal Neoplasms; Aldosterone; Ascites; Breast Neoplasms; Female; Humans; Male; Renin; Sodium; Sp | 1982 |
[Iatrogenic gynecomastia in aldosterone-antagonist therapy].
Topics: Breast Neoplasms; Gynecomastia; Humans; Male; Middle Aged; Spironolactone | 1981 |
[Breast cancer in the male].
Topics: Breast Neoplasms; Cimetidine; Digitalis Glycosides; Humans; Isoniazid; Male; Risk Factors; Sex Facto | 1993 |
Letter: Breast cancer associated with administration of spironolactone.
Topics: Aged; Breast; Breast Neoplasms; Cell Transformation, Neoplastic; Female; Humans; Middle Aged; Recept | 1975 |
Letter: Breast cancer and spironolactone.
Topics: Breast Neoplasms; Female; Male; Spironolactone | 1975 |